• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Should Investors Believe in Bounces as Markets Get Choppy?

Sector selection will remain paramount as pandemic effects continue to permeate.
By KEVIN CURRAN Dec 01, 2021 | 10:30 AM EST
Stocks quotes in this article: MRNA, REGN, MRK, BNTX, PFE, JNJ

Uncertainty is the word of the day as the impact of the Omicron variant of Covid-19 is a cause for trepidation among investors, sending markets on a rollercoaster ride.

The initial news of the new variant, first detected in southern Africa, sent markets spiraling. Amid the panic, market indexes saw their largest declines in months, with travel, hospitality, and energy stocks taking the biggest hits in a holiday-shortened trading session.

However, as Monday morning rolled around, the market seemed to be taking a more optimistic outlook. Pershing Square CEO Bill Ackman perhaps best summed up this rosier outlook as the new week of trading began.

"While it is too early to have definitive data, early reported data suggest that the Omicron virus causes 'mild to moderate' symptoms (less severity) and is more transmissible," Ackman said in a tweet Sunday evening. "If this turns out to be true, this is bullish not bearish for markets."

Tuesday morning was a repeat of Friday amid increased apprehension on the strain and the potential effectiveness of vaccines (in addition to comments from Fed Chair Jerome Powell), only to see Wednesday morning mirror Monday's action for a bounce.

As the volatility wins out, investors may be asking whether they can really believe any bounce as Ackman suggests, or if the worst is yet to come.

Assessing Omicron

The main cause for anxiety in the markets at present is not just the new variant, but its potential to be more virulent and, perhaps, more deadly.

"This variant has a large number of mutations, some of which are concerning," the WHO said in a report on the new variant. "Preliminary evidence suggests an increased risk of reinfection with this variant, as compared to other VOCs."

The international organization further noted that the number of cases in its epicenter in South Africa continue to surge more rapidly than other variants.

Adding to concern are comments from pharmaceutical leaders like Moderna (MRNA) CEO Stéphane Bancel who indicated the current vaccines might not curtail its spread.

"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta," he told the Financial Times in an interview. "I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'"

Expectations from Regeneron (REGN) and its monoclonal antibody treatments as well as Merck's (MRK) pill were also noted as likely lagging in efficacy against the new variant.

Studying Previous Strains

However, it is a look at these previous strains, such as the Delta variant that roiled markets earlier this year, that might offer investors the best roadmap to handle the current market volatility.

As investors will certainly recall, Delta led to a major decline in indexes early in the year, only to form a base for a rally as vaccines proved effective in deterring the impact. As Omicron now emerges, investors must be feeling a sense of deja vu.

Yet, the important tact for investors might be in the competition of these strains rather than just the emergence of the latest mutation.

"The accumulation of variations and its initial detection in Africa suggest that our fears have been realized," Citi analyst Andrew Baum told investors in a note. "Concern over [Omicron] needs to be balanced against the failure of other concerning variants such as Beta to outcompete Delta."

Indeed, this is a crucial point for investors to watch, as even the WHO that initially came out with an abundance of caution has since softened its stance on a comparison to Delta.

"It is not yet clear whether Omicron is more transmissible compared to other variants, including Delta," the organization wrote in an update on Sunday. "The number of people testing positive has risen in areas of South Africa affected by this variant, but epidemiologic studies are underway to understand if it is because of Omicron or other factors."

Further, despite some cautious words from Moderna, Regeneron, Merck and others, there is an air of confidence among executives of global health organizations.

"We know that viruses mutate, and we're prepared," Emer Cooke, the executive director of the European Medicines Agency, told the European Parliament's health committee Tuesday, as an example.

The conviction on this end is likely bolstered by German vaccine leader BionTech SE (BNTX) and its American partner Pfizer's (PFE) ability to make vaccines that are capable of contending with variants. That is not to mention the rapid development of their initial vaccine that proved incredibly effective at reducing risk of hospitalization and death even through these successive mutations.

Sector Selection

So, if this more sanguine view of markets appears a sane one amid the abundance of uncertainty, one would be inclined to deploy more capital into an apparently discounted market. Stilll, sector selection will remain paramount as pandemic effects continue to permeate.

"Last week's selloff on Friday was likely the combination of uncertainty around a new virus strain, coupled with long holiday weekend illiquidity," Sylvia Jablonski Kampaktsis told Real Money. "It felt like a knee jerk reaction, and the past versions of this have happened somewhat quickly and, as time goes on, with a more shallow impact on the market."

However, she noted that sector selection will remain key as pandemic effects continue to spread. Primarily, she noted that high-quality tech dragged down by broader moves are a good place to start, while airline, cruise and hotel stocks could be best positioned for a "bounce-back" trade.

"The travel industry took close to $5 trillion out of the economy, and it hasn't recovered," Kampaktsis noted. "That bodes well for a bounce-back trade, but keep in mind it will take some time to pan out."

She added finally that banks appear well positioned ahead of potential rate hikes and were likely unfairly battered on Friday. This theme is particularly interesting to note as Fed chair Jerome Powell offers more commentary indicating increased concern on inflation. His commentary in his second day of testimony on Wednesday will be crucial for investors to keep an eye on.

Patrick Liu, senior financial analyst at the Singapore-based hedge fund JJ Richman, largely agreed with Kampaktsis in expecting investors to seek out discounts in depressed sectors.

"Banks and travel stocks, including airlines and cruise operators, are likely to get a bit of lift from bargain hunters," he told Real Money. "Although the ones that will inevitably get the most attention would be pharma, particularly vaccine manufacturers such as Johnson & Johnson (JNJ) , Moderna, Pfizer as they move towards adjusting and reformulating their vaccines to the Omicron variant."

Finally, there is some speculation that energy stocks could be an appetizing opportunity as pandemic concerns drive concerns over demand. Should the variant prove less deleterious than the presently pessimistic mood suggests, the sector could be set for another surge. Wednesday morning's action in the WTI and Brent indexes are certainly indicative of this action.

For more on finding an entry point in oil stocks specifically, read Carley Garner's piece on support levels for investors to stay apprised of.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Curran was long PFE and XLE.

TAGS: Federal Reserve | Investing | Markets | Oil | Stocks | Trading | Value Investing | VIX | U.S. Equity | Coronavirus

More from Stocks

More Good Dividend Stocks With Pretty Charts

Bruce Kamich
Jan 27, 2023 1:31 PM EST

In this second part of a two-part series, we look at the final five of 10 stocks with the best of the both worlds.

Even Some Out of Fashion Names Are Now Back in Style

Jonathan Heller
Jan 27, 2023 12:30 PM EST

Sure, we're only one month in to 2023, but so far these stocks are starting the new year with a bang.

I'm Making Small Bets With These 2 Stocks

Bret Jensen
Jan 27, 2023 11:30 AM EST

While I remain cautious on the overall market, I continue to act upon the limited opportunities I'm finding in the current market.

Chevron Is Crushing It and for My Portfolio Too: Here's the Trade

Stephen Guilfoyle
Jan 27, 2023 10:51 AM EST

The only reason to exit the stock now is profit-taking.

Adani Companies Plunge Under Hindenburg Attack, Hurting Secondary Sale Attempt

Alex Frew McMillan
Jan 27, 2023 9:30 AM EST

Retail investors may baulk now they are being offered Adani Enterprises shares at a range well above their current trading price.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:48 AM EST REAL MONEY

    Watch Doug Kass on the Daily Rundown!

    In today's Action Alerts PLUS Daily Rundown, Doug ...
  • 11:03 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend On Real Money

    It's time to start using this power to build great...
  • 03:06 PM EST BOB LANG

    LEAPS Webinar

    This week, I offered a free webinar session talkin...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login